Tag Archives | biotech stocks

Biotech Rally Moving Toward April Highs: ASCO and M&A Provides Underlying Support…Update-1

Update June 1… After Close Biotech Holds…Uh oh CNBC is talking about biotech. IBB 281.18, XBI 58.18 This stealth rally has been going steady for two weeks but now CNBC and its “Fast Money” show are talking up biotech so is this a jinx? And saying “party over” when the rally just started?? “Options Action” […]

Continue Reading 0

BIO Investor Forum 2015 Next Week…Update

10/21 I will be posting articles from the Meeting later this week and next week. 2015 Bio Investor Forum October 20-21, 2015 We will be attending the Bio Investor Forum 2015 in San Francisco next week. Various panels will cover important biotherapy topics such as oncology trends, precision medicine and full genome analysis and valuation […]

Continue Reading 0

Biotech Bull Market: Top ETFs Outperform Mutual Funds Over 2 Years

Can Healthcare/Biotechnology Funds Outperform ETFs in 2015? In January of 2013 we compared three of the most liquid life science ETFs to some of the top mutual funds in the sector. Review our 2013 summary but the conclusion at that time was that ETFs provided better returns than mutual funds over a five year period […]

Continue Reading 0

Tepid Rally Favors Large Caps: ABBV, GILD, RHHBY

Healthcare Stocks trail other sectors up 0.34%,  Energy  up 0.8%,  Financials up 0.73% and Technology up 0.77% But biotech ETFs are in the Green Biotechnology stocks were mixed today with the following winners among our large cap picks: Gilead Sciences (GILD) up 1.26%, Roche Holding (RHHBY) up 1.08% and Regeneron up 0.58%. Our large cap […]

Continue Reading 0

ETFs Outperformed Managed Biotechnology Funds YTD-FBT Is the Leader

2014 YTD- ETFs Outperformed Managed Funds In Biotech In the past managed life science funds outperformed ETFs but this has reversed in 2014. Fidelity’s flagship Select Biotechnology Portfolio (FBIOX) is up 10% YTD and 41.4% over one year, and 229.6% over 5 years.  The fund is concentrated in large cap and mid cap stocks; Gilead […]

Continue Reading 0

Green Day-Biotechs Are Running Again: ALKS, BIIB, GILD, VRTX

Life Science Stocks Moving Again-XBI up 1.54% After a 15%+ move January YTD you would think it is time to step back and take some off. Today the rally was in a full bull MOde with biopharmaceutical stocks leading the way. Here are big upside movers among our focus stocks: ALKS up 2%, BIIB up […]

Continue Reading 0

Fidelity Select Biotechnology Fund (FBIOX) Outperforms Biotech ETFs YTD

Life Science Sector at or Near YTD and All Time Highs Fidelity Fund (FBIOX) Outperform ETFs Over the past 3 years we reviewed how ETFs complement a biotechnology  investment strategy and compared three of the largest and most liquid : FBT, IBB and XBI (see the articles below and our comprehensive article from May 2011). […]

Continue Reading 0

Big Money and Celebrity Financial News: Icahn Effect Redux

 The Stock Market Realty Shows In case you missed it stocks lately are being driven by hedge funds and celebrity billionaires who tout their positions. The Icahn vs Ackman drama is the latest high profile realty show featured mainly by CNBC-TV. Biotechnology stocks have always been driven by  a BIG money following and we covered an […]

Continue Reading 0

Will The Biotechnology Bull Market Stimulate Venture Investing?

Notes from the BioInvestor Forum October 9-12–Biotech Investing The BioInvestor Forum held every year at this time in San Francisco is one of the premier events for emerging companies. Over 500 investors and companies attended with 7 major sessions on investing and innovation trends. Over 100 private and public companies made a 20 minute presentation. […]

Continue Reading 0

Biotech Stocks Fly Over Macro Flack: ALXN, ILMN, REGN, TMO

Rayno Life Science Focus Stocks Are Strong-TMO Added Biopharmaceutical stocks continue their run today beginning with higher sales expectations for Regeneron(REGN $128) with their eye drug for macular degeneration.Regeneron raised expectation for Eyelea to $700-750 from $500-550.Total revenue for Q2 was $304.4 with a profit up to $76.7M or 70 cents a share. The stock […]

Continue Reading 0